



FILE COPY

Receipt

PATENT
Attorney Docket No.: SCRIP1200-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Griffin and Zlokovic Art Unit: 1647
Application No.: 09/777,484 Examiner: B. Bunner
Filed: February 5, 2001
Title: NEUROPROTECTIVE, ANTITHROMBOTIC AND ANTI-
INFLAMMATORY USES OF ACTIVATED PROTEIN C (APC)

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

JUN 19 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in connection with the above-identified patent application,
please find the following:

- (1) Request for Corrected Filing Receipt; (2 pgs)
- (2) Copy of Filing Receipt reflecting changes; (2 pgs) and
- (3) Return postcard.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are
being deposited with the United States Postal Service as first class
mail on this date, 5-29-03, in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231

Ginia N. Najar
(Name of Person mailing Paper)

Ginia N. Najar
(Signature of Person Mailing Paper)

5-29-03
Date

Application No.: 09/777,484
Applicant: Griffin, et. al.
Filed: February 5, 2001
Page 2


PATENT
Attorney Docket No.: SCRIP1200-1

No fee is deemed necessary in connection with the filing of this paper. However, if any fee is required, the Commissioner is hereby authorized to charge the amount of this fee, or credit any overpayments, to Deposit Account No. 50-1355. A copy of this Transmittal Letter is enclosed.

Respectfully submitted,

Date:

May 29, 2003



Richard J. Imbra
Registration No. 37,643
Telephone: (858) 677-1496
Facsimile: (858) 677-1465

USPTO CUSTOMER NO. 28213

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133



PATENT
Attorney Docket No.: SCRIP1200-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Griffin and Zlokovic Art Unit: 1647
Application No.: 09/777,484 Examiner: B. Bunner
Filed: February 5, 2001
Title: NEUROPROTECTIVE, ANTITHROMBOTIC AND ANTI-
INFLAMMATORY USES OF ACTIVATED PROTEIN C (APC)

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

JUN 19 2003

TECH CENTER 1600/2900

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

This Communication is submitted to request correction of the filing receipt in reference to the above-identified application. The data requiring correction is indicated in yellow highlight on the attached copy of the filing receipt and herein in **BOLD**.

Please change the Middle Initial of the second inventor from "Y" to -V-.

Applicants accordingly request the correction be made of record.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, 5-29-03, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

Yinita M. Nazar
(Name of Person mailing Paper)

Yinita M. Nazar
(Signature of Person Mailing Paper)

5-29-03
Date


Application No.: 09/777,484
Applicant: Griffin, et. al.
Filed: February 5, 2001
Page 2

PATENT
Attorney Docket No.: SCRIP1200-1

No fee is deemed necessary in connection with the filing of this paper. However, if any fee is required, the Commissioner is hereby authorized to charge the amount of this fee, or credit any overpayments, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: May 29, 2003


Richard J. Imbra
Registration No. 37,643
Telephone: (858) 677-1496
Facsimile: (858) 677-1465

USPTO CUSTOMER NO. 28213

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133



RECEIVED

OCT 24 2001

JUN 19 2003

Page 1 of 2

TECH CENTER 1600/2900

GRAYCARY/GT PATENT
UNITED STATES PATENT AND TRADEMARK OFFICECOMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/777,484	02/05/2001	1645	672	SCRIP1200-1	8	21	3

CONFIRMATION NO. 8867

UPDATED FILING RECEIPT



OC000000006924677

Lisa A. Haile, Ph.D.
Gray Cary Ware & Freidenrich LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189

Date Mailed: 10/17/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)John H. Griffin, Del Mar, CA;
Berislav X. Zlokovic, Rochester, NY;

-V-

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/180,227 02/04/2000

Foreign Applications

If Required, Foreign Filing License Granted 03/13/2001

Projected Publication Date: 01/24/2002

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ******Title**

Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC)

Preliminary Class

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).